Prostate Cancer Differential Diagnosis

Key points
- Not all patients with an elevated PSA concentration have CaP.
- Although the benefit of screening was recently shown in one randomized Canadian study, several questions have been raised about the data analysis (Labrie et al, 1999).
- In summary, many factors must be considered by both clinicians and their patients who are contemplating screening for prostate cancer.
- Other factors that elevate serum PSA include BPH, urethral instrumentation, infection, prostatic infarction, or vigorous prostate massage.
Differential Diagnosis
Not all patients with an elevated PSA concentration have CaP. Other factors that elevate serum PSA include BPH, urethral instrumentation, infection, prostatic infarction, or vigorous prostate massage. Induration of the prostate is associated not only with CaP, but also with chronic granulomatous prostatitis, previous TURP or needle biopsy, or prostatic calculi. Sclerotic lesions on plain x-ray films and elevated levels of alkaline phosphatase can be seen in Paget disease and can often be difficult to distinguish from metastatic CaP. In Paget disease, PSA levels are usually normal and x-ray findings demonstrate subperiosteal cortical thickening.
Screening for CaP
The case for CaP screening is supported by the following: The disease is burdensome in this country; PSA improves detection of clinically important tumors without significantly increasing the detection of unimportant tumors; most PSA-detected tumors are curable; prostate cancer mortality is declining in regions where screening occurs; and curative treatments are available. Although the benefit of screening was recently shown in one randomized Canadian study, several questions have been raised about the data analysis (Labrie et al, 1999). Two large randomized clinical trials to assess the benefit of screening are ongoing. In the Prostate, Lung, Colon and Ovarian Trial (PLCOT), 74,000 men have been randomized to annual DRE and PSA screening versus no screening. Results are anticipated in 2006. A larger trial involving 190,000 men in the European Randomized Study for Prostate Cancer Screening is anticipated to provide results in 2008. The efficacy of treatment is being examined in Scandinavia, where two randomized trials compare watchful waiting with radiation therapy or radical prostatectomy. A similar trial, Prostate Cancer Intervention Versus Observation Trial (PIVOT), is under way in the United States. Such trials, although imperfect, may give us the information we need before prostate cancer screening and treatment can be recommended with confidence.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMen with asthma less likely to develop lethal prostate cancer
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of…
19 May 2015
NewsMoffitt researchers work to determine why some prostate cancer patients experience more hot flashes
Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer. But nearly 80 percent of patients who receive ADT report experiencing hot flashes during and after…
9 May 2015
NewsI've Been Diagnosed with Prostate Cancer
A diagnosis of prostate cancer was made. At the time of your routine annual physical examination, suspicion was raised either because of an elevation in your serum prostate-specific antigen (PSA) level or an abnormality…





